AI-generated analysis. Always verify with the original filing.
Adagio Medical Holdings, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting a net loss of $3.3 million for Q4 2025 and $25.1 million for the full year, alongside key business updates including the completion of enrollment in its FULCRUM-VT pivotal trial and a private placement raising up to $50 million.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth
. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated March 26, 2026 104 Cover Page Interactive D
| Metric | Value | Basis |
|---|---|---|
| Cost of Revenue | $58.00 | |
| Research and Development Expenses | $2.24 | |
| Selling, General and Administrative Expenses | $1.68 | |
| Net Loss | $3.31 | |
| Basic Net Loss Per Share | $0.16 | |
| Diluted Net Loss Per Share | $0.21 | |
| Cost of Revenue | $0.70 | |
| Research and Development Expenses | $10.60 | |
| Selling, General and Administrative Expenses | $10.60 | |
| Net Loss | $25.10 |
Sean Salmon
Marie-Claude Jacques
Antwan Gipson